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Renal structure in early autosomal-dominant polycystic kidney
disease (ADPKD): The Consortium for Radiologic Imaging
Studies of Polycystic Kidney Disease (CRISP) cohort
Background. Autosomal-dominant polycystic kidney disease
(ADPKD) is characterized by gradual renal enlargement and
cyst growth prior to loss of renal function. Standard radio-
graphic imaging has not provided the resolution and accuracy
necessary to detect small changes in renal volume or to reliably
measure renal cyst volumes. The Consortium for Radiologic
Imaging Studies in Polycystic Kidney Disease (CRISP) is longi-
tudinally observing ADPKD individuals using high-resolution
magnetic resonance (MR) imaging to determine if change in
renal and cyst volumes can be detected over a short period of
time, and if they correlate with decline in renal function early
in disease.
Methods. Standardization studies were conducted in phan-
toms and four subjects at each participating clinical center.
After, in the full-scale protocol, healthy ADPKD individuals
15 to 45 years old with creatinine clearance70 mL/min under-
went standardized MR renal imaging, renal iothalamate clear-
ance, comprehensive clinical evaluation, and determination of
24-hour urinary albumin and electrolyte excretion. Stereology
was used from T1-weighted images to quantify renal volume,
and region-growing thresholding was used from T2-weighted
images to determine cyst volume. Renal structures were evalu-
ated in relation to demographic, clinical, and biochemical vari-
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ables using means/medians, standard deviations, and Pearson
correlations.
Results. Reliability coefficients for MR renal and cyst vol-
ume measurements in phantoms were 99.9% and 89.2%, re-
spectively. In the full-scale protocol, 241 ADPKD individuals
(145 women and 96 men) were enrolled. Total renal, cyst, and
% cyst volume were significantly greater in each decade group.
Hypertensive individuals demonstrated greater renal, cyst, and
% cyst volume than normotensive subjects. Age-adjusted renal
(r  0.31, P  0.0001), cyst (r  0.36, P  0.0001), and %
cyst volume (r  0.35, P  0.0001) were inversely related to
glomerular filtration rate (GFR). Age-adjusted renal volume
(r  0.42, P  0.0001), cystic (r  0.39, P  0.0001, and %
cyst volume (r  0.41, P  0.0001) were related with urinary
albumin excretion.
Conclusion. MR measures of renal and cyst volume are reli-
able and accurate in patients with ADPKD. ADPKD is charac-
terized by significant cystic involvement that increases with
age. Structure (renal and cyst volume) and function (GFR)
are inversely related and directly related with the presence of
hypertension and urinary albumin excretion in individuals with
normal renal function.
Autosomal-dominant polycystic kidney disease
(ADPKD) is a systemic, inherited disorder characterized
by renal cyst growth and enlargement leading to renal
failure [1]. ADPKD is the most common genetic renal
disorder and is the third most common single cause of
end-stage renal disease (ESRD) in the United States.
The average age of entry into ESRD is 57 years [2],
indicating a slowly progressive disorder where renal
function is maintained within the normal range for de-
cades. Franz and Reubi [3] proposed that renal function
remains stable in ADPKD patients for years, followed
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by a sharp decline in glomerular filtration rate (GFR)
once a critical renal size is reached. In support of this
hypothesis, in the largest series of ADPKD patients re-
ported, ESRD occurred within 5 years in all patients
when kidneys were detected on physical examination
[4]. As well, in ADPKD patients with established renal
insufficiency, decline in renal function is universal, with a
rate of decline of approximately 5 mL/min/year reported
from a large prospective series using iothalamate renal
clearance determinations [5].
The majority of ADPKD patients develop extensive
renal enlargement with volumes many fold greater than
normal prior to loss of renal function [6], indicating that
normal renal architecture is lost early. Given the magni-
tude of renal distortion prior to loss of function, the
potential for successful therapeutic intervention is low
when individuals with established renal insufficiency are
treated, and may account in part for the lack of successful
interventional trials designed to slow the progression of
renal disease in ADPKD [5, 7]. Evaluating the effective-
ness of therapeutic agents early in the course of ADPKD
is difficult, given the long (usually more than 40 years)
period during which renal function remains normal.
Therefore, it is necessary to identify reliable markers of
disease progression other than renal function that can
detect progression over a relatively short period of time
in ADPKD.
Increased renal volume predicts and is associated with
loss of renal function in ADPKD [8, 9]. Of note, renal
cystic involvement measured by computed tomography
(CT) scanning [10, 11] in two studies predicted renal
outcome more reliably than total renal volume. These
studies involved nine subjects with an average GFR of
91 mL/min/1.73 m2 and a median prospective follow-up
of 8 years in one study [10] and ten subjects with an
average GFR of 86 mL/min/1.73 m2 and a median retro-
spective follow-up of 5 years in the other [11]. Given the
small number of patients, the potential additional value
of cyst volume and the probable greater accuracy of
currently available imaging techniques, these observa-
tions are worthy of more extensive study.
The Consortium for Radiologic Imaging Studies of
Polycystic Kidney Disease (CRISP) was created to de-
velop innovative imaging techniques and analyses using
magnetic resonance (MR) imaging to reliably and accu-
rately measure cyst and renal volume in ADPKD indi-
viduals early in the course of their disease. The purpose
of this study was to determine if (1) renal or cyst volume
can be measured reliably and accurately; (2) change in
renal or cyst volume can be detected over a relatively
short period of time; and (3) an increase in cyst or renal
volume is associated with loss of renal function in
ADPKD. Given that CRISP’s primary goal is to develop
imaging methods to follow disease progression or to eval-
uate treatments for ADPKD, different vendors for MR
Fig. 1. Large and small phantoms of polycystic kidneys used in the
standardization protocol.
image acquisitions at different participating clinical cen-
ters (PCCs) are being used. A standardization protocol
was first developed involving phantoms and four subjects
evaluated at each PCC to determine the accuracy and
reliability of the proposed methods.
After completion of the standardization study, a full-
scale longitudinal observational protocol was developed
by CRISP and implemented with the goal of prospec-
tively following a large number of ADPKD individuals
early in the course of disease for a 3-year period. In addi-
tion, concurrent studies evaluating the relative accuracy
of ultrasound as compared to MR imaging and the quan-
tification of renal blood flow using MR techniques are
being evaluated. We now report the results of the stan-
dardization protocol and the baseline characteristics of
the individuals that comprise the CRISP cohort.
METHODS
Study organization
PCCs in this study include the Mayo Foundation, the
University of Alabama at Birmingham, Emory Univer-
sity, and the University of Kansas Medical Center. Wash-
ington University in St. Louis is the Data Coordinating
and Image Analysis Center (DCIAC). The Division of
Kidney, Urologic, and Hematologic Diseases of the Na-
tional Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), National Institutes of Health, is a
voting member of this cooperative agreement. The role
of the DCIAC is to collect images from the collaborating
institutions, segment and analyze the images, store and
record the results using a Web-based data entry system,
and to perform statistical analyses.
Standardization protocol
Large and small ADPKD phantoms (Fig. 1) to simu-
late kidneys of different size were constructed by the
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DCIAC and a different set of phantoms was sent to each
PCC. The phantoms were designed to test the accuracy
and reliability of the MR imaging methods proposed for
the full-scale clinical trial. The phantoms consisted of
water-filled balloons (cysts), agarose (kidney paren-
chyma), and vegetable oil (perinephric fat). The shape
of both types of phantom was made reniform by solidify-
ing the agarose in a kidney-shaped mold. The large phan-
tom (Fig. 1A) is shown with the mold containing the
phantom and the small phantom is shown next to it
(Fig. 1B). The volume of balloons in the phantoms was
between 2 and 20 mL. The volumes of the phantoms and
balloons were measured separately by fluid displacement
method and this was used as the renal volume gold stan-
dard to compare with those measured by the image-
based method. The MR acquisition sequences for these
studies were identical to those used in the large-scale
clinical trials except that no gadolinium contrast was
used. Each phantom (large and small) was scanned once,
repositioned, and scanned again.
Following approval of a study protocol by the Steering
Committee and local Institutional Review Boards, four
participants (one from each PCC) were sent to each
PCC for MR imaging. Subjects were selected who would
otherwise be considered eligible for the full-scale clinical
protocol. Subjects were chosen to represent the full range
of possible kidney sizes expected to be in the full-scale
protocol. The four participating subjects were scanned
at each PCC between July 13, 2000 and September 13,
2000, using a protocol similar to that outlined in the full-
scale protocol. No subject was studied less than 1 week
apart. Three of these subjects subsequently enrolled in
the full-scale study.
Full-scale protocol
Eligible subjects were enrolled in CRISP funded through
cooperative agreements by the Division of Kidney, Uro-
logic, and Hematologic Diseases of the NIDDK, Na-
tional Institutes of Health. The recruitment period ex-
tended from December 1, 2000 to October 20, 2001.
Recruitment goals for the study were to enroll 210 indi-
viduals. Potential subjects were recruited from four PCC
sites. Prior to enrollment, each potentially eligible sub-
ject underwent a verbally informed written consent pro-
cess. Consent forms were developed and reviewed by the
Steering Committee of CRISP, approved by an NIDDK-
appointed External Advisory Committee, and then sub-
mitted to each PCC’s Institutional Review Board for site-
specific approval. Subjects were recruited from referring
physicians, local advertisements, contact with the local
Friend’s Groups of the Polycystic Kidney Disease Foun-
dation, and the national Polycystic Kidney Disease Foun-
dation.
ADPKD subjects were eligible for enrollment if they
were older than 15 years of age and younger than 46
years of age. ADPKD was defined based on the criteria
of Ravine [12]. Men were eligible if their serum creati-
nine concentrations were 1.6 mg/dL and women were
eligible if their serum creatinine concentrations were
1.4 mg/dL. All subjects were required to have a 24-hour
creatinine clearance70 mL/min/1.73 m2 or a Cockcroft-
Gault estimate of creatinine clearance 70 mL/min to
participate.
Subjects were ineligible to participate if they had un-
dergone renal surgery, had cyst drainage procedures,
were unable to undergo breath-held MR imaging, had
distorting foreign bodies or aneurysmal clips, had other
systemic diseases potentially affecting renal function, or
had other medical conditions that included significant
thrombocytopenia, neutropenia, anemia, liver disease,
known intracranial aneurysms, pregnancy, lactation, or
who were less than 6 months postpartum. In addition,
individuals determined by the principal investigator to
be unable to complete the consent process or reliably
complete the 3 years of study were excluded from study.
Risk stratification for progression to renal failure was
a part of the subject recruitment plan. Recruitment strat-
egies were aimed at including equal numbers of men
and women and equal distribution of subjects in each
decade of the acceptable age range. In addition, recruit-
ment goals included having at least two thirds high-risk
individuals participate to increase the likelihood that dis-
ease progression would occur during the study. Individuals
were considered high risk if hypertension was diagnosed
before the age 35 years, ADPKD was diagnosed in utero
or in the first year of life, 24-hour urinary protein excre-
tion was greater than 300 mg/day on any occasion, or a
single episode of gross hematuria in men prior to age 30
was present [8, 13, 14]. Low risk was defined as an individual
with no previous risk factors and who was older than 35
years of age, and indeterminate risk was defined as an
individual with no risk factors and who was younger than
35 years of age. After screening and enrollment, subjects
underwent an extensive medical history, including com-
plications related to ADPKD, method and year of diag-
nosis of ADPKD, previous hospitalizations or surgeries,
and prescription medication and over-the-counter medi-
cation use. A history of hypertension was sought and
defined as those previously diagnosed who were cur-
rently taking antihypertensive medications or those with
systolic and diastolic blood pressures 140/90 mm Hg on
three consecutive visits during participation in the study.
After screening and enrollment, subjects were sched-
uled for a 2-day evaluation at their clinical site, either
as an outpatient at the research clinic (University of Kan-
sas) or as an inpatient on the General Clinical Research
Center (GCRC) (University of Alabama in Birmingham,
Emory University, and the Mayo Foundation). The pro-
tocols were developed, standardized, and reviewed by
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the Steering Committee to ensure that evaluations would
be conducted similarly at each of the PCCs.
Enrolled subjects were instructed to continue their
current medications and to discontinue nonsteroidal
anti-inflammatory agent medication intake for at least 7
days prior to evaluation. Subjects were not to initiate
diuretic therapy within 14 days of evaluation. During the
day prior to admission for baseline evaluation, subjects
collected a 24-hour urine sample for the determination
of creatinine, sodium, potassium, urea, and albumin ex-
cretions. Microalbuminuria was defined as 30 mg/day
urinary albumin excretion.
All subjects underwent several determinations using
standardized methods. Weight and height were deter-
mined at the time of admission. Blood pressures were
measured in the left and right arm in the morning, prior
to antihypertensive medication intake, after being seated
for at least 5 minutes on three occasions 3 minutes apart
using an oscillometric measuring device. Subjects then
stood for 5 minutes and their blood pressure was mea-
sured three times in the arm that demonstrated the high-
est reading in the seated position.
Blood was obtained prior to GFR studies for the deter-
mination of serum electrolyte, liver enzyme, hemoglobin,
and total cholesterol concentrations and platelet and
white cell counts. Blood was obtained from all participat-
ing African Americans to screen for the presence of
sickle cell trait or disease or thallasemia using hemoglo-
bin electrophoresis. All samples were collected into pre-
chilled tubes and placed on ice before being centrifuged
and separated and frozen at 80C until assayed.
MR imaging
All subjects underwent a standardized MR imaging
protocol developed by the Imaging Committee and ap-
proved by the Steering Committee. Subjects were stud-
ied in the morning prior to medication intake and break-
fast. MR images were obtained at each clinical site by a
trained MR technologist or imaging specialist. Although
all MR scanners were 1.5 T scanners, scanners at each
site were either of different model or manufacturer. The
University of Alabama at Birmingham used GE LXI
(General Electric Medical Systems, Milwaukee, WI, USA),
Emory University used Gyroscan (Philips Medical Sys-
tems, Best-Leiden, The Netherlands), the Mayo Founda-
tion used GE Sigma (General Electric Medical Systems,
Milwaukee, WI, USA), and the University of Kansas
Medical Center used Magnetron Vision Plus (Siemens
Medical Systems, Iselin, NJ, USA). Prior to each study,
the MR scanner was adjusted for proper shimming. A 20-
gauge intravenous angiocatheter was placed and infused
with normal saline solution to maintain venous patency
during the course of imaging. Electrocardiographic
(ECG) pads were placed for ECG gating. Subjects were
placed supine on the MR table with their arms either at
their side or over their shoulders. A phased-array surface
coil was positioned with its center over the inferior costal
margin, estimated as the upper margin of the kidney.
During this time, breath-holding instructions were given
to the subjects. Scout scans were performed to locate
the scan range of the entire kidney. Axial images were
obtained that covered the most anterocaudal and poster-
ocranial aspects of the kidneys. The field of view was
maintained between 30 and 35 cm.
Breath-held coronal T2-weighted images [single shot
fast spin echo/half-Fourier acquired single turbo spin-
echo (SSFSE/HASTE)] with fat saturation were obtained
with 3 and 9 mm fixed, slice thickness and an image
adjusted for a slice thickness between 3 and 9 mm in
order to cover the kidneys with a single breath-hold.
Neighboring image groups were overlapped by the desig-
nated slice thickness for each image acquisition. After
the acquisition of T2-weighted images, three-dimensional
volumetric interpolated breath-hold examination/fast
multi-slice spoiled gradient echo (VIBE/FMPSPGR) co-
ronal T1-wighted images without fat saturation were ob-
tained with 3 mm fixed slice thickness. Following this,
gadolinium was injected at 1 mL/second for a total of
20 to 30 mL or 0.1 mmol/kg. T1-weighted images were
repeated with 3 mm slice thickness 120 and 180 seconds
after initiation of the gadolinium injection. Following
these image acquisitions, subjects were removed from
the MR table and returned to the research clinic, for
completion of the remaining studies.
GFR studies: Nonisotopic iothalamate renal clearances
Subjects were instructed not to eat food after midnight
but to continue oral hydration. Subjects ingested no less
than 600 mL of water prior to obtaining background io-
thalamate samples. After oral hydration, a blank urine
and plasma sample was collected prior to injection of
iothalamate meglumine (Conray 60%). Iothalamate (300
mg) was injected subcutaneously followed by a 60-
minute equilibration period. Blood and urine samples
were then collected within 5 minutes of each other, and
bladder emptying was monitored by ultrasonography.
The urine sample from this collection was discarded and
the time of voiding was recorded. After 45 minutes, blood
and urine samples were collected with the times and urine
volume recorded. Bladder emptying was monitored by
ultrasound. The studies were considered satisfactorily
completed if ultrasound monitoring of the bladder dem-
onstrated 20 mL or 10% residual urine volume. Urine
and plasma samples were immediately centrifuged, ali-
quotted, and packaged for shipping to the Mayo Medical
Laboratories for measurement of iothalamate concentra-
tion [15].
MR image transfer
MR images were retrieved to a work station and thor-
oughly inspected to determine if image quality was ade-
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quate. The images were then transferred in Digital Imaging
and Communications in Medicine (DICOM) format to the
DCIAC for further image analysis [16].
Standardization study measurements of cyst and renal
volume in phantoms and subjects
Both large and small phantoms were measured by two
analysts. For the small phantoms, each of four phantoms
was imaged twice and measured twice by each of two
analysts (4  2  2  2  32 measurements); the same
design was used for the large phantoms. For measuring
the small phantom balloon cysts, each of four phantoms
was imaged twice and measured once by each of the two
analysts (4  2  2  16 measurements); the same
design was used for the large phantoms. Three analysts
evaluated the images from the standardization subjects
for kidney and cyst volume. A two thirds fractional de-
sign was used to examine the images, as every image
was analyzed by two of the three analysts and each com-
bination of analysts examined one third of the images.
Cyst and renal volume measurements in subjects
After receiving the images sent via DICOM encoding
from the four centers, the images were analyzed to mea-
sure kidney and renal cyst volumes. Kidney volumes
were measured from T1-weighted images using the stere-
ology method and renal cyst volume from T2-weighted
images using the region-based thresholding method.
These segmentation methods were chosen to yield reli-
able and accurate volumetric measurements with high
efficiency. The stereology method has been validated
using MR-acquired images in a variety of different or-
gans [17–21] and is simple and fast method of segmenting
an object by counting the number of intersections of a
randomly oriented and positioned grid over the object.
In this technique, the area of the kidney in each image
was calculated from the collection of selected points that
overlaid the kidney regions and by converting the point
count to a pixel count to obtain the area measurements.
The total kidney volume was calculated from the set of
contiguous images by summing the products of the area
measurements and the slice thickness.
A region-based thresholding method was used to cal-
culate cyst volumes [17]. A threshold was selected inter-
actively by an analyst using T2-weighted images. Cysts
were brighter than the renal parenchyma in T2-weighted
images and were segmented from voxels with intensity
values greater than the threshold. Cyst areas were calcu-
lated in each image, and the total cyst volume was calcu-
lated from each set of contiguous images by summing
the products of the area measurements and the slice
thickness. Noncystic volume was determined by sub-
tracting total cyst volume from total renal volume for
each kidney. Percent cyst volume was determined from
the ratio of cyst volume to total renal volume [17–21].
Laboratory analyses
Urinary albumin concentrations were determined us-
ing a double antibody albumin radioimmunoassay. So-
dium and potassium were determined by ion-selective
electrode or flame photometry. Serum and urine creati-
nine concentrations were determined by an automated
spectrophotometric method using the monochromatic
calorimetric determination of the Janovsky complex.
Urinary urea concentrations were determined using the
urease method.
Statistic methods
Image analysis estimates of renal and cyst volume in
the standardization protocol were examined to deter-
mine the reliability of two methods. An incomplete facto-
rial design was employed, in which each scan was mea-
sured by two of the three analysts. Additionally, each
analyst measured each image twice. Sources of variability
included subject, image location, analyst, and repetition.
In computing reliability using such variance compo-
nents, r  2s/(2s  k 2n). 2s or signal variance is the
subject component, while 2n is defined by one of several
nuisance factors (analyst, location, repetition) and k is
defined by the number of distinct nuisance sources (for
instance, k 3 when analyst is considered). The reliabil-
ity of each component of potential contribution to analy-
sis variability was examined separately. Since this design
was not completely balanced, methods for incomplete
designs were employed in evaluation using PROC
MIXED in SAS (SAS Institute, Cary, NC, USA).
The percentage, mean [	 standard deviation (SD)],
and median values were used to describe study character-
istics. Associations of categoric measures were tested by
chi-square, analysis of variance (ANOVA), and two-
tailed Student t test analyses, with a P value 0.05 con-
sidered to be significant. The Pearson correlation was
used to examine the association between interval vari-
ables. Variables not normally distributed such as urinary
albumin and protein excretion were log-transformed
prior to analysis. Data analyses were conducted utilizing
SAS for Windows, version 8.0 (SAS Institute).
RESULTS
Standardization protocol
Phantom studies demonstrated high accuracy in mea-
surement of total renal and cyst volumes by MR imaging.
True total renal and cyst volume measurements, ob-
tained by fluid displacement techniques are presented in
Table 1. The two sets of images (obtained from different
positioning of the two types of phantoms) were measured
two different times by two different analysts using the
stereology technique to determine total renal volume.
The collection of 64 volume measurements was exam-
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Table 1. True and measured whole (renal) and balloon (cystic) volumes in large and small phantoms
True volume Measured mean volume (SD) Proportion of true
Location Size Whole Balloon Whole Balloon Whole Balloon
Alabama Large 621.0 222 607.0 (6.3) 230.4 (35.0) 0.977 1.038
Small 255.5 82 252.9 (2.7) 86.9 (11.7) 0.989 1.060
Mayo Large 599.0 190 586.4 (3.6) 205.9 (16.1) 0.979 1.084
Small 276.5 68 283.0 (12.8) 68.8 (10.0) 1.024 1.012
Emory Large 646.0 235 622.3 (13.7) 249.4 (13.2) 0.963 1.061
Small 257.0 70 251.0 (9.7) 73.8 (7.1) 0.977 1.054
Kansas Large 617.0 220 614.8 (5.2) 223.0 (13.1) 0.996 1.014
Small 262.0 69 259.0 (4.7) 63.4 (8.4) 0.989 0.919
Table 2. Interclass coefficients (reliability measures) of clinical
variables measured in the standardization protocol subjects
Reliability
Variable Mean	SD Range (intraclass r )
Height cm 175.75	16.51 167–200.5 0.998
Weight kg 71.20	24.72 56.7–108.1 0.990
BMI m2 22.47	3.05 20.33–26.89 0.951
BSA m2 1.86	0.40 1.63–2.49 0.998
GFR mL/min/1.73 m2 94.75	30.55 66–137 0.857
Abbreviations are: BMI, body mass index; BSA, body surface area; GFR,
glomerular filtration rate.
ined using variance components methods in SAS PROC
MIXED. Using this approach, the reliability coefficient
for “analyst” was 0.994. The reliability coefficient for
“positioning” was 0.992. For the balloon components of
the phantoms, balloons in the two sets of images were
measured once by the two analysts so that 32 measure-
ments were available for analysis. With this data, the
reliability coefficient for the “analyst” component was
0.892. The variance component for “positioning” was
too small for a valid estimate and no reliability value
was computed.
Statistics pertaining to the measured clinical variables
and the reliability values, computed using the intraclass
correlation approach of the four participating subjects,
are presented in Table 2. These statistics are based on
16 measurements total in four individuals of each vari-
able. For GFR measurements 14 of 16 studies were con-
sidered suitable for testing for intraclass correlations.
The mean age of the four participating subjects (three
women, one man, three Caucasians, one African Ameri-
can) was 36 	 8.4 years; range, 21 to 45 years. Excellent
reliability of measurement was found for all clinical vari-
ables (Table 2).
Representative coronal T2-weighted MR images in a
single subject from each PCCs are shown in Figure 2.
Renal and cyst volume measurements from the four sub-
jects participating in the standardization protocol are
presented in Table 3. The reliability of the measurement
process was examined using the variance components
method. For the kidney volume measurement using ste-
reology, the reliability for “analyst” was 0.998. For the
cyst volume measurement, the reliability for “analyst”
was 0.961 and “location” was 0.962.
Full-scale clinical protocol
A total of 241 ADPKD subjects from 211 families
were successfully enrolled in the CRISP study. Charac-
teristics of the cohort are presented in Table 4. Of the
241 subjects enrolled in the study, 96 were men and
145 were women. A total of 289 eligible subjects were
screened and the 48 eligible who did not enroll did not
differ significantly from those currently participating in
the study with regard to age, risk stratification, or gender
distribution (data not shown). Of those enrolled, 209
(86%) participants were Caucasian, 28 (12%) were Afri-
can American, two (1%) were Hispanic, and two (1%)
were Asian. Two African Americans demonstrated evi-
dence for sickle cell trait. No other heritable hematologic
abnormalities were noted. The mean age of diagnosis of
ADPKD of this cohort was 24.5 	 9.4 years. A positive
family history (asymptomatic family screening) accounted
for 41% of subjects diagnosed and 59% were diagnosed
based on signs and symptoms related to the disease.
Risk included 56% of individuals at high risk, 24% were
definite low risk, and 20% were indeterminate.
Prior to admission to the study, 62% of subjects were
hypertensive (Table 5). Of those, 80% were receiving anti-
hypertensive medications, and 22% of these required
more than one medication to control blood pressure.
The most common antihypertensive medication used was
an angiotensin-converting enzyme (ACE) inhibitor (51%),
followed by an angiotensin receptor blocker (21%), a
diuretic (13%), calcium channel blocker (10%), and 

blocker (10%). Hypertensive individuals were older,
with greater blood pressures, lower GFR, and higher
urinary albumin excretion compared to their normoten-
sive counterparts (Table 5).
In the CRISP cohort, left total renal (570.00 	 364.9
mL vs. 507.2 	 328.2 mL, P  0.0001) and noncystic
(292.9	 110.5 mL vs. 269.7	 104.8 mL, P 0.0001) were
greater than the right. Men demonstrated significantly
greater noncystic volumes than women (630.0 	 227.7
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Fig. 2. T2-weighted images obtained using a
single shot fast spin echo/half-Fourier acquired
single turbo spin echo (SSFSE/HASTE) se-
quence during the standardization study in the
same subject at each participating clinical cen-
ter. (A) University of Alabama at Birmingham.
(B ) Emory University School of Medicine.
(C ) University of Kansas Medical Center. (D )
the Mayo Foundation.
Table 3. Mean renal and cyst volumes of four subjects measured at each participating clinical center
Measurement location
Patient Overall
Measurement type source statistics Emory Kansas Mayo Alabama
Stereology renal volume Emory 2552.5 (80.8) 2417.9 (19.2) 2584.2 (47.9) 2584.0 (99.3) 2556.5 (35.9)
KU 906.0 (46.6) 945.6 (15.0) 839.3 (19.1) 927.5 (15.7) 931.4 (15.9)
Mayo 542.0 (18.2) 548.5 (18.6) 553.7 (3.6) 523.2 (11.2) 549.1 (18.9)
UAB 1074.6 (25.8) 1105.3 (14.4) 1078.2 (13.0) 1088.3 (5.1) 1042.1 (17.7)
Thresholding cyst volume Emory 1442.8 (184.5) 1334.9 (248.9) 1269.2 (257.2) 1568.5 (59.9) 1490.9 (63.0)
KU 206.4 (19.1) 221.5 (8.2) 191.6 (4.1) 202.2 (7.3) 225.4 (23.7)
Mayo 163.3 (19.0) 152.6 (11.5) 179.2 (23.8) 144.7 (5.1) 165.9 (0.5)
UAB 285.2 (51.1) 288.0 (60.6) 296.3 (64.6) 262.9 (62.6) 296.3 (58.8)
Data presented as the mean volume measurement of two separate images at each site performed by two observers for each image. Standard deviations of the
measurement are presented. Abbreviations are: KU, Kansas University; UAB, University of Alabama at Birmingham; Emory, Emory University; Mayo, the Mayo
Foundation.
Table 4. Clinical characteristics of autosomal-dominant polycystic kidney disease (ADPKD) men and women enrolled in the Consortium
for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort
Women Men
Variable Mean	SD N  145 N  96 P value
Age years 33.8	8.9 34.0	9.0 33.5	8.8 0.6500
Weight kg 77.0	18.4 69.7	15.8 88.1	16.6 0.0001
BMI m2 25.9	5.2 25.5	5.6 26.5	4.7 0.1230
SBP mm Hg 125.1	13.6 122.7	14.0 128.5	12.3 0.0011
DBP mm Hg 83.4	10.7 83.2	11.0 83.6	10.4 0.7836
MAP mm Hg 98.2	10.9 97.4	11.5 99.4	9.7 0.1773
Serum creatinine mg/dL 1.0	0.2 0.9	0.2 1.1	0.2 0.0001
GFR mL/mm/1.73 m2 98.2	24.9 99.8	26.6 95.8	22.1 0.2199
Sodium excretion mEq/day 185.5	87.2 162.0	74.8 220.9	92.8 0.0001
Potassium excretion mEq/day 56.5	24.7 51.1	21.3 64.7	27.3 0.0001
Albumin excretion mg/day 42.4	60.9 39.4	48.2 47.0	76.2 0.3961
Total cholesterol mg/dL 172.9	37.0 169.2	34.1 178.6	40.6 0.0559
HDL mg/dL 49.2	22.6 51.8	12.5 45.3	31.96 0.0674
LDL mg/dL 102.4	34.3 97.6	28.9 109.8	40.2 0.0130
Triglycerides mg/dL 120.2	95.0 102.4	63.0 147.5	125.0 0.0026
Abbreviations are: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; GFR, glomerular filtration
rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
mL vs. 516.9 	 179.4 mL, P  0.0002), although no
significant differences in total renal or cyst volume were
found. In the CRISP cohort (Fig. 3), mean cystic, total
renal, and noncystic volumes were greater than mean
total renal volumes reported in healthy individuals [22],
with the exception of mean cystic volume in the 15 to
24 year age group. Total renal, cystic, and noncystic
volume was significantly greater in the 25 to 34 year age
group and 35 to 45 year age group as compared to the
15 to 24 year age group (Fig. 3). As well, cyst and total
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Table 5. Clinical characteristics of hypertensive and normotensive autosomal-dominant polycystic kidney disease (ADPKD) individuals
enrolled in the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort
Normotensives Hypertensives
Variable N  93 N  148 P value
Age years 31.0	9.3 35.5	8.3 0.0001
Weight kg 73.6	15.7 79.2	19.6 0.0157
BMI m2 24.8	4.5 26.6	5.6 0.0049
SBP mm Hg 121.3	13.5 127.4	13.2 0.0008
DBP mm Hg 79.9	10.4 85.5	10.4 0.0001
MAP mm Hg 94.5	10.8 100.4	10.3 0.0001
Serum creatinine mg/dL 0.9	0.2 1.0	0.2 0.0001
GFR mL/mm/1.73 m2 106.8	20.2 92.8	26.1 0.0001
Sodium excretion mEq/day 183.1	86.8 187.0	87.7 0.7431
Potassium excretion mEq/day 56.5	28.2 56.5	22.5 0.9990
Albumin excretion mg/day 33.0	45.2 48.4	68.4 0.0430
Total cholesterol mg/dL 168.2	36.7 175.9	37.1 0.1260
HDL mg/dL 48.6	13.7 49.6	26.7 0.7111
LDL mg/dL 101.3	33.0 103.2	35.1 0.6830
Triglycerides mg/dL 106.5	99.9 128.2	91.4 0.1073
Abbreviations are: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; GFR, glomerular filtration
rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Fig. 3. Mean total renal, cystic, and noncystic volumes in the entire
Consortium for Radiologic Imaging Studies of Polycystic Kidney Dis-
ease (CRISP) cohort, in those between 15 to 24, 25 to 34, and 35 to 45
years of age. Total renal, cyst, and noncystic volumes were significantly
greater in the 25 to 34 and 35 to 45 year age group as compared to the
15 to 24 year age group (*) (P  0.0001) and in the 35 to 45 year age
group as compared to 25 to 34 year age group () (P  0.002). Symbols
are ( ), total renal volume; ( ) noncystic volume; () cystic volume;
(- - -) reported renal volumes in the general population.
renal volume were significantly greater in the 35 to 45
year age group as compared to the 25 to 34 year age
group. Total renal, cystic, and noncystic volumes were
greater in hypertensive as compared to normotensive
individuals (Fig. 4). Cyst volume measurements ac-
counted for a large proportion of the variability of the
measurement of total renal volume (57%). African
American individuals demonstrated similar age (33.4 	
10.2 years vs. 33.8 	 8.8 years) and GFR (105.8 	 24.1
mL/min/1.73 m2 vs. 97.9	 24.9 mL/min/1.73m2) but dem-
Fig. 4. Mean total renal, cystic, and non-cystic volumes in hypertensive
(HBP) (N  151) and normotensive (NBP) (N  90) autosomal-domi-
nant polycystic kidney disease (ADPKD) individuals. Total renal, cystic,
and noncystic volumes were significantly greater in the hypertensive
individuals (*) (P  0.0001). Symbols are ( ), total renal volume; ( )
noncystic volume; () cystic volume.
onstrated significantly smaller noncystic volumes (461.1 	
179.6 mL vs. 572.8 	 200.3 mL, P  0.02) as compared
to Caucasians.
Renal volume (r  0.39, P  0.0001), cyst volume
(r  0.45, P  0.0001), and % cyst volume (r  0.44,
P  0.0001) were inversely related to GFR (Fig. 5).
As well, GFR and age were significantly and inversely
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Fig. 5. Relationship between glomerular filtration rate (GFR) and age-
adjusted mean renal volume (A ), mean cyst volume (B ), and % cyst
volume (C ) in 236 autosomal-dominant polycystic kidney disease
(ADPKD) individuals with relatively intact renal function.
related (r0.40, P  0.0001). Using linear age adjust-
ment, the correlations between GFR and renal volume
(r  0.31, P  0.0001), cyst volume (r  0.36, P 
0.0001), and % cyst volume (r  0.35, P  0.0001)
remained significant. Mean 24-hour urinary albumin ex-
cretion in the cohort was 42.4 	 60.6 mg/day and micro-
albuminuria (30 mg/day) was present in 37% of sub-
jects. Renal volume (r  0.42, P  0.0001), cyst volume
(r  0.39, P  0.0001), and % cyst volume (r  0.31,
P  0.0001) were related to urinary albumin excretion.
Age-adjusted partial correlations between urinary albu-
min excretion and renal structural parameters and cyst
volume were unchanged by this adjustment.
DISCUSSION
This study demonstrates that renal and cyst volume
can be accurately and reliably measured in ADPKD
individuals with significant structural involvement using
currently available MR imaging techniques. This method
of image acquisition avoids the potential pitfalls of oper-
ator-dependent techniques or the need for multiple im-
age acquisitions of large kidneys when ultrasonographic
methods are employed. As well, MR-based image acqui-
sition avoids the radiation exposure associated with CT
or the need for the administration of iodinated contrast
to allow for enhancement of the cyst images. Using these
techniques, cyst volumes can be reliably separated from
total renal volumes to begin to understand the process
of disease progression in human ADPKD.
The process of measurement in phantoms and subjects
using stereology can be used to generate scientifically
meaningful measurements. Reliability values were high
because the values obtained from the different sources
(analysts and other variables) showed consistency and
repeatability. In addition, the four subjects in the stan-
dardization study had renal volumes that differed greatly
(542 to 2552 mL). When computing the reliability of the
measurement, the “signal” variance was thus very large,
enabling the measurement process to show very high re-
liability. Importantly, the reliability indexes were stronger
for structural (renal and cyst volume) as compared to
functional (GFR) measures.
Although significant training and retraining was neces-
sary for the analysts prior to performing the standardiza-
tion study, these results indicate that this format for mea-
surement of renal and cyst volume can be implemented
for the purposes of performing clinical investigation. The
average rate of increase of renal volume using ultrasound
techniques and the ellipsoid formula in 229 unselected
ADPKD individuals studied over a large (7 years) pe-
riod of time with a wide range of renal function was 46	
55 mL [9]. This increase, as well as the rates reported in
two smaller studies using CT [10, 11], indicate that the
imaging methods used in this study will be able to detect
small changes in renal and cyst size over a short period
of time early in ADPKD.
In the full-scale clinical trial, the CRISP cohort was a
population similar to other unselected ADPKD cohorts
with relatively intact renal function, where 40% were
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asymptomatic at the time of diagnosis and the majority
demonstrated hypertension [4, 6, 23]. Importantly, this
group of subjects demonstrated significant disease bur-
den, although they were early in the course of the disease.
Mean total renal volume for the CRISP cohort was ap-
proximately fourfold greater than total renal volume re-
ported in the general population [22, 24], with on average
more than 39% of total renal volume accounted for by
the presence of renal cysts. Left total renal, cystic, and
noncystic volumes were greater than in the right kidney,
similar to reports of greater left as compared to right
renal volume in the general population [22]. The contri-
bution of cyst volume to the variability of total renal
volume measured was 94.5%, the most significant contri-
bution to renal enlargement in ADPKD. In conjunction
with these observations, we have demonstrated signifi-
cantly lower renal blood flow and increased renal vascu-
lar resistance in the left as compared to right kidney in
ADPKD patients, potentially accounting for the differ-
ences in disease severity found (King et al, submitted
for publication).
Mean noncystic volumes were 562.6 	 207.5 mL and
were greater than expected for “nondiseased” or reported
normal renal volume. As well, men demonstrated sig-
nificantly greater noncystic volumes than women. At pres-
ent, the causes of increased noncystic renal volume found
in this cohort are not completely understood. Volume-
averaging effects during image analysis or small cysts
undetected by MR image acquisition and image analyses
or other noncystic structural abnormalities such as in-
creased extracellular matrix and interstitial fibrosis may
be present [25, 26].
Age was an important determinant of renal structural
involvement in this cohort as reported elsewhere [3, 4,
8, 9, 23]. Renal, cystic, and noncystic volumes were sig-
nificantly greater in individuals older than 25 years of
age, with further increases in total and cyst volume seen
in those 35 years of age as compared to those between
25 and 35 years of age. Although age was an important
factor in determining renal and cyst volume, other impor-
tant clinical variables were found to be independently
related.
Structure-function relationships in ADPKD patients
with relatively intact renal function have been investi-
gated with regard to hypertension [6]. However, volume-
function relationships in ADPKD individuals with intact
renal function have not been previously reported. In this
study, GFR was inversely related to all measured renal
components after adjusting for age with % cyst volume
demonstrating the closest relationship as reported by
others [10, 11]. Importantly, this cross-sectional report
demonstrates significant disease burden (an average
fivefold greater size compared to normal individuals) in
ADPKD patients with normal renal function. This level
of disease severity indicates a significant amount of
asymptomatic disease progression in ADPKD patients.
It will be important to determine if the relationship be-
tween change in structure correlates with change in func-
tion in this group of subjects. As well, increased urinary
albumin excretion predicts renal outcome in ADPKD
[14] with microalbuminuria found in ADPKD individu-
als with established renal insufficiency and hypertension
[3, 4, 10, 11, 14]. In this cohort of ADPKD individuals
with relatively intact renal function, microalbuminuria
was present in 37% and significant relationships between
GFR, urinary albumin excretion, and total renal, cystic,
and % cyst volume were found. These observations un-
derscore the importance of structure-function relation-
ships early in ADPKD and that renal volume and its
components may be a reliable marker of disease severity.
CONCLUSION
Innovative imaging and image analysis developed by
CRISP allowed for accurate and reliable measures of cyst
and renal volume in ADPKD. Using these techniques,
markers of disease severity such as hypertension status
and urinary albumin excretion are related to the level
of renal function and renal volume early in the course
of disease.
ACKNOWLEDGMENTS
This study was supported by the UO1-DK56956 grant for the Na-
tional Institute of Diabetes and Digestive and Kidney Diseases and
the General Clinical Research Center grants MO1-RR00039 (Emory
University), MO1-RR00052 (University of Alabama at Birmingham),
and MO1-RR00585 (the Mayo Foundation) for the Division of Re-
search Resources, National Institutes of Health. The authors greatly
appreciate the assistance of the study coordinators, Diane Watkins,
MAS; Lorna Stevens, RN; Jody Mahan, RN; and Pam Truell, RN. These
data were presented in part at the American Society of Nephrology
2002 Annual Meeting, Sunday November 3, 2002, Philadelphia, PA.
Reprint requests to Arlene B. Chapman, M.D., Emory University
School of Medicine, 1639 Pierce Drive, WMB 338, Atlanta, GA 30322.
E-mail: arlene_chapman@emory.org
REFERENCES
1. Grantham JJ: Polycystic kidney disease: From the bedside to the
gene and back. Curr Opin Nephrol Hypertens 10:533–542, 2001
2. Neugarten J, Acharya A, Silbiger SR: Effect of gender on the
progression of nondiabetic renal disease. J Am Soc Nephrol 11:319–
329, 2000
3. Franz KA, Reubi FC: Rate of functional deterioration in polycys-
tic kidney disease. Kidney Int 239:526–529, 1983
4. Dalgaard OZ: A follow-up of two hundred eighty-four patients
and their families. Acta Med Scand 328:1–255, 1957
5. Klahr S, Breyer JA, Beck GJ, et al: Dietary protein restriction,
blood pressure control and the progression of polycystic kidney
disease. Modification of Diet in Renal Disease Study Group. J Am
Soc Nephrol 5:2037–2047, 1995
6. Gabow PA, Chapman AB, Johnson AM, et al: Renal structure
and hypertension in autosomal dominant polycystic kidney disease.
Kidney Int 38:1177–1180, 1990
7. Ecder T, Chapman AB, Brosnahan GM, et al: Effect of antihyper-
tensive therapy on renal function and urinary albumin excretion in
Chapman et al: Renal structure in early ADPKD: Results of the CRISP cohort 1045
hypertensive patients with autosomal dominant polycystic kidney
disease. Am J Kidney Dis 35:427–432, 2000
8. Gabow PA, Johnson AM, Kaehny WD, et al: Factors affecting
the progression of renal disease in autosomal dominant polycystic
kidney disease. Kidney Int 41:1311–1319, 1992
9. Fick-Brosnahan GM, Belz MM, McFann KK, et al: Relationship
between renal volume growth and renal function in autosomal
dominant polycystic kidney disease: a longitudinal study. Am J
Kidney Dis 39:1127–1134, 2002
10. King BF, Reed JE, Bergstralh EJ, et al: Quantification and longi-
tudinal trends of kidney, renal cysts, and renal parenchyma vol-
umes in autosomal dominant polycystic kidney disease. J Am Soc
Nephrol 11:1505–1511, 2000
11. Sise C, Kusaka M, Wetzel LH, et al: Volumetric determination
of progression in autosomal dominant polycystic kidney disease
by computed tomography. Kidney Int 58:2492–2501, 2000
12. Ravine D: Evaluation of ultrasonographic diagnostic criteria for
autosomal dominant polycystic kidney disease. Lancet 1:824–827,
1994
13. Johnson AM, Gabow PA: Identification of patients with auto-
somal dominant polycystic kidney disease at highest risk for end-
stage renal disease. J Am Soc Nephrol 8:1560–1567, 1997
14. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt
proteinuria and microalbuminuria in autosomal dominant polycys-
tic kidney disease. J Am Soc Nephrol 5:1349–1354, 1994
15. Bergert JH, Liedtke RR, Oda RP, et al: Development of a non-
isotopic capillary electrophoresis-based method for measuring glo-
merular filtration rate. Electrophoresis 18:1827–1835, 1997
16. Moore SM, Maffitt DR, Blaine GJ, Bae KT: Workstation acquisi-
tion node for multicenter imaging studies, in Medical Imaging 2001:
PACS and Integrated Medical Information Systems: Design and
Evaluation (volume 4323), edited by Siegel EL, Huang HK, San
Diego, SPIE, 2001, pp 271–277
17. Bae KT, Commean PK, Lee J: Volumetric measurement of renal
cysts and parenchyma using MRI: Phantoms and patients with
polycystic kidney disease. J Comput Assist Tomogr 24:614–619,
2000
18. Walton JM, Roberts N, Whitehouse GH: Measurement of the
quadriceps femoris muscle using magnetic resonance and ultra-
sound imaging. Br J Sports Med 31:59–64, 1997
19. Ladekarl M, Jensen V, Nielsen B: Stereologic estimation of
breast tumor size. Anal Quant Cytol Histol 18:151–157, 1996
20. Keshavan MS, Anderson S, Beckwith C, et al: A comparison of
stereology and segmentation techniques for volumetric measure-
ments of lateral ventricles in magnetic resonance imaging. Psychia-
try Res 61:53–60, 1995
21. Roberts N, Garden AS, Cruz-Orive LM, et al: Estimation of
fetal volume by magnetic resonance imaging and stereology. Br J
Radiol 67:1067–1077, 1994
22. Moell H: Size of normal kidneys. Acta Radiol 46:640–645, 1956
23. Iglesias CG, Torres VE, Offord KP, et al: Epidemiology of adult
polycystic kidney disease, Olmstead County, Minnesota: 1935–
1980. Am J Kidney Dis 2:630–639, 1983
24. Lerman LO, Flickinger AL, Sheedy PF, 2nd, Turner ST: Repro-
ducibility of human kidney perfusion and volume determinations
with electron beam computed tomography. Invest Radiol 31:204–
210, 1996
25. Milutinovic J, Agodoa LY: Potential causes and pathogenesis in
autosomal dominant polycystic kidney disease. Nephron 33:139–
144, 1983
26. Zeier M, Fehrenbach P, Geberth S, et al: Renal histology in
polycystic kidney disease with incipient and advanced renal failure.
Kidney Int 42:1259–1265, 1992
